Expanding regulatory science: Regulatory complementarity and reliance
- PMID: 37957894
- PMCID: PMC10766020
- DOI: 10.1111/cts.13683
Expanding regulatory science: Regulatory complementarity and reliance
Abstract
Drug regulatory institutions, infrastructures, and systems are becoming increasingly interconnected across national boundaries and increasingly global in outlook. This process is reflected in the broadening and deepening application of the principles and practice of Regulatory Reliance, and parallel initiatives to strengthen the capacities of regulatory institutions in low- and middle-income countries (LMICs). Although these developments are important and constructive, they have tended to be framed in terms of the transfer of systems, knowledge, and skills from relatively "mature" regulatory agencies in high-income countries (HICs) to less-well-resourced regulatory agencies in LMICs. This framing recognizes and foregrounds the considerable practical challenges that many LMIC regulatory agencies face, but in doing so, also backgrounds and underestimates the significance of the different contextual insights that LMIC health researchers and regulators can bring to the regulatory deliberations of their HIC counterparts. This position paper argues that the systematic pursuit, identification, and sharing of these different contextual insights-a dimension of regulatory science that we term "Regulatory Complementarity"-can augment the current practice and goals of Regulatory Reliance, and further invigorate the emerging global regulatory ecosystem.
© 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Conflict of interest statement
The authors declared no competing interests for this work.
References
-
- Vaz A, Santos MR, Gwaza L, et al. WHO collaborative registration procedure using stringent regulatory authorities' medicine evaluation: reliance in action? Exp Rev Clin Pharmacol. 2022;15(1):11‐17. - PubMed
-
- Project ORBIS . https://www.fda.gov/about‐fda/oncology‐center‐excellence/project‐orbis Accessed September 13, 2023
-
- European Medicines Agency . Questions and Answers on the Pilot Project ‘OPEN.’ 2021. https://www.ema.europa.eu/en/documents/other/questions‐answers‐pilot‐pro... Accessed 01/06/2023.
-
- Public Health Threats . https://www.ema.europa.eu/en/human‐regulatory/overview/public‐health‐thr... Accessed September 13, 2023.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical